Lantern Pharma (NASDAQ: LTRN), a clinical-stage, AI-driven precision oncology company, has received regulatory and Institutional Review Board approvals in Taiwan to open Part 2 of its Phase 2 HARMONIC trial of LP-300. The lead Taiwan site is now open to accrual and actively screening patients, with additional IRB approvals anticipated at two more sites in the fourth quarter. This development matters because it expands the trial's geographic reach and patient access, potentially accelerating the development of a therapy specifically for patients with the EGFR exon 21 L858R mutation—a subset that often has limited options after progressing on tyrosine kinase inhibitors.
In the United States, a central IRB has approved the amended protocol, and clinical sites have begun identifying patients with the L858R mutation. Part 2 will enroll patients who have progressed after TKI treatment and will allow LP-300 to be administered for up to eight cycles in combination with carboplatin and pemetrexed, up from six cycles previously. This protocol amendment is significant because it may enhance the drug's efficacy by extending the treatment duration, potentially leading to better outcomes for this difficult-to-treat population.
Preliminary data showed median progression-free survival of 8.9 months among nine L858R patients who completed six cycles, compared with 8.3 months among all 16 L858R patients evaluated. While the company cautions that these findings are preliminary, exploratory, and based on small patient numbers, the trend suggests a potential benefit for those who complete the full course of therapy. If the eight-cycle regimen yields further improvements, it could strengthen LP-300's position as a promising candidate for this biomarker-defined group. For investors, this progress signals that Lantern's AI-driven approach, which leverages its RADR platform to identify likely responders, is advancing in the clinic. To view the full press release, visit https://ibn.fm/CqeDR.
Lantern Pharma's pipeline includes LP-184 (zirdafulven), LP-300, and LP-284, along with its central-nervous-system-focused subsidiary, Starlight Therapeutics, and its AI subsidiary, Open-Medicine AI. The latest news and updates relating to LTRN are available in the company's newsroom at https://ibn.fm/LTRN. As a specialized communications platform, BioMedWire is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, delivering access to a vast network of wire solutions via InvestorWire to efficiently reach diverse markets. The platform also offers editorial syndication to 5,000+ outlets and enhanced press release enhancement to ensure maximum impact. These services help companies like Lantern Pharma gain visibility among investors and industry stakeholders.
The Taiwan approvals represent a critical step in Lantern's strategy to validate LP-300 in a biomarker-selected population. By expanding the trial to Taiwan, the company can tap into a diverse patient pool and potentially expedite enrollment, which is often a bottleneck in oncology trials. Moreover, the amended protocol allowing eight cycles could provide more robust data on the drug's efficacy and safety. If successful, LP-300 could address a significant unmet need for patients with the EGFR L858R mutation, who often develop resistance to existing therapies. This progress also underscores the value of Lantern's AI platform in guiding clinical development, potentially reducing the time and cost of bringing new cancer treatments to market.
